About Tenpoint Therapeutics Tenpoint Therapeutics is a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting therapeutics for ophthalmic indications with significant unmet medical need, including presbyopia, cataracts, and geographic atrophy. Our lead investigational asset, BRIMOCHOL™ PF, is designed to be the first and only combination therapy for presbyopia and has received a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. We are actively advancing preparations for a commercial launch in the first half of 2026. We know our people are the driving force behind the success of our mission and vision. That’s why we offer a competitive benefit package to attract the very best talent to our team and to take care of our employees and their families. Below is a snapshot of our U.S. benefits package for full-time employees. Generous medical, dental, and vision health insurance plans Flexible spending accounts for health and dependent care Short-term, long-term, and life/AD&D insurance Employee Assistance Program 20 paid vacation days, 12 paid holidays, and 12 sick days 401(k) Retirement Plan with 100% company match up to 4% and immediate vesting Hybrid work options Wellness Resources Stock Options For more information, visit www.tenpointherapeutics.com and follow us on LinkedIn , X , and Instagram .